The state of Montana currently has 2 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Billings, Missoula, Great Falls and Kalispell.
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
03/19/2024
Locations: Carl Thornblade, MD, PLLC, Missoula, Montana
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
Recruiting
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.
Gender:
All
Ages:
2 years and above
Trial Updated:
01/28/2022
Locations: Dermavant Clinical Site, Missoula, Montana
Conditions: Atopic Dermatitis